Cited by 202Adipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and MetabolismCardiovascular Disease and Adiposity

Central Role of the Adipocyte in the Metabolic Syndrome

Bergman, Richard N., Van Citters, Gregg W., Mittelman, Steven D., Dea, Melvin K., Hamilton-Wessler, Marianthe, Kim, Stella P., Ellmerer, Martin·2001·Journal of Investigative Medicine

Abstract

Insulin resistance is associated with a plethora of chronic illnesses, including Type 2 diabetes, dyslipidemia, clotting dysfunction, and colon cancer. The relationship between obesity and insulin resistance is well established, and an increase in obesity in Western countries is implicated in increased incidence of diabetes and other diseases. Central, or visceral, adiposity has been particularly associated with insulin resistance; however, the mechanisms responsible for this association are unclear. Our laboratory has been studying the physiological mechanisms relating visceral adiposity and insulin resistance. Moderate fat feeding of the dog yields a model reminiscent of the metabolic syndrome, including visceral adiposity, hyperinsulinemia, and insulin resistance. We propose that insulin resistance of the liver derives from a relative increase in the delivery of free fatty acids (FFA) from the omental fat depot to the liver (via the portal vein). Increased delivery results from 1) more stored lipids in omental depot, 2) severe insulin resistance of the central fat depot, and 3) possible regulation of visceral lipolysis by the central nervous system. The significance of portal FFA delivery results from the importance of FFA in the control of liver glucose production. Insulin regulates liver glucose output primarily via control of adipocyte lipolysis. Thus, because FFA regulate the liver, it is expected that visceral adiposity will enhance delivery of FFA to the liver and make the liver relatively insulin resistant. It is of interest how the intact organism compensates for insulin resistance secondary to visceral fat deposition. While part of the compensation is enhanced B-cell sensitivity to glucose, an equally important component is reduced liver insulin clearance, which allows for a greater fraction of B-cell insulin secretion to bypass liver degradation, to enter the systemic circulation, and to result in hyperinsulinemic compensation. The signal(s) resulting in B-cell up-regulation and reduced liver insulin clearance with visceral adiposity is (are) unknown, but it appears that the glucagon-like peptide (GLP-1) hormone plays an important role. The integrated response of the organism to central adiposity is complex, involving several organs and tissue beds. An investigation into the integrated response may help to explain the features of the metabolic syndrome.

Integrity signals

Registry

Crossref · 10.2310/6650.2001.34108

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bergman, R. N., Van Citters, G. W., Mittelman, S. D., Dea, M. K., Hamilton-Wessler, M., Kim, S. P., & Ellmerer, M.
Affiliations
  • University of Southern California (US)
  • From the Department of Physiology and Biophysics, Keck School of Medicine and University of Southern California Diabetes Research Center, Los Angeles, Calif
Corresponding author
Bergman, Richard N.
Venue
Journal of Investigative Medicine
Published
2001-01
Volume
49
Issue
1
Pages
119-126
ISSN
  • 1081-5589 (ISSN-L)
  • 1708-8267
OpenAlex
W1983548385
Cited by
202
References
29
Citations by year
2026: 1 · 2024: 4 · 2023: 2 · 2022: 5 · 2021: 4 · 2020: 2 · 2019: 2 · 2018: 5 · 2017: 6 · 2016: 4 · 2015: 2 · 2014: 6 · 2013: 9 · 2012: 7
FWCI
3.38
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Investigative Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute on Aging (T32 AG 00093, T32AG000093)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK029867, DK27619, DK29867)
Topics
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
Keywords
metabolic syndrome, insulin resistance, visceral fat, free fatty acids, hepatic insulin resistance, hyperinsulinemia, glucagon-like peptide-1, dyslipidemia, type 2 diabetes
MeSH terms
Animals, Diabetes Mellitus, Type 2, Dietary Fats, Dogs, Fatty Acids, Nonesterified, Humans, Insulin Resistance, Models, Biological, Obesity, Adipocytes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review